Isofol Medical AB (publ) (STO: ISOFOL)

Market Cap	388.44M
Revenue (ttm)	n/a
Net Income (ttm)	-39.27M
Shares Out	161.52M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	350,066
Open	2.500
Previous Close	2.500
Day's Range	2.320 - 2.525
52-Week Range	0.522 - 4.885
Beta	2.04
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 19, 2025

About Isofol Medical AB

Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ISOFOL

Financial Performance

In 2023, Isofol Medical AB's revenue was 721,000, a decrease of -94.37% compared to the previous year's 12.80 million. Losses were -37.07 million, -76.80% less than in 2022.